Critically, superior progression-free survival was associated with heightened immune score (HR=0.52, P=0.01), ESTIMATE score (HR=0.61, P=0.06), and Tumor purity (HR=1.92, P=0.02), confirming that HMGA2-mediated immunosuppression may contribute to poor prognosis through inhibition of anti-tumor immunity (Figures 2E–G). This evidence concerns the gene HMGA2 and neoplasm.